ACMG 2025 oral presentation: Administration of eladocagene exuparvovec using the SmartFlow magnetic resonance-compatible ventricular cannula in pediatric patients with aromatic L-amino acid decarboxylase deficiency
This oral presentation, presented at ACMG 2025, assesses the pharmacodynamics of eladocagene exuparvovec using the SmartFlow magnetic resonance (MR)-compatible ventricular cannula in pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency
- Understand the SmartFlow MR-compatible ventricular cannula for intraputaminal administration
- Review the pharmacodynamics of eladocagene exuparvovec through cerebrospinal fluid homovanillic acid levels and putaminal-specific [18F] fluorodopa uptake in patients with AADC deficiency
- Learn about the safety of bilateral intraputaminal infusion of eladocagene exuparvovec in pediatric patients
MED-US-CORP-2500008 | November 2025
This poster was developed and funded by PTC Therapeutics for ACMG 2025.
Thank you!
Already registered?
Register now to access the content on this page
Already registered?
If not, register below
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
MED-US-CORP-2600001 | February 2026
COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.